Revvity (RVTY) Q2 2026 earnings review
Divestiture Clears the Deck, Powering a Guidance Raise
Revvity delivered a strong Q2, driven by a surging Diagnostics segment and the strategic removal of its troubled China Immunodiagnostics (IDX) business. By shedding the China IDX anchor, pro forma organic growth hit 3%. However, the underlying segment dynamics have sharply diverged: Diagnostics accelerated to a massive 11% pro forma organic growth, completely offsetting a surprising 3% decline in Life Sciences. Bolstered by a cleaner portfolio and a $16M one-time tariff refund, management confidently raised FY26 pro forma guidance across the board.
🐂 Bull Case
The definitive agreement to divest China IDX removes Revvity's biggest growth headwind. The result is an immediate structural upgrade to the company's margin and organic growth profile.
Management raised FY26 pro forma revenue, organic growth (to 4-5%), and adjusted EPS (to $5.35 midpoint), signaling high confidence in the back half of the year.
🐻 Bear Case
Life Sciences pro forma organic revenue reversed into negative territory (-3%). If pharma/biotech end markets don't stabilize, Diagnostics cannot carry the entire company forever.
The impressive $1.41 adjusted EPS includes a $0.11 boost from a $16M tariff-related refund. Without this one-time injection, the earnings beat looks much more pedestrian.
⚖️ Verdict: 🟢
Bullish. The strategic decision to cut the China IDX business is already paying dividends. While Life Sciences weakness is a genuine concern, the overall portfolio is now significantly cleaner, more profitable, and growing faster.
Key Themes
China IDX Divestiture Finalized
The definitive agreement to divest the China Immunodiagnostics business is a transformative catalyst. Previously a persistent drag due to China's DRG policy changes, removing this segment structurally improves Revvity's financial profile. Pro forma Q2 operating profit margin stepped up to 13.2% from a reported 12.2%, proving the immediate accretive nature of this portfolio pruning.
Diagnostics Takes the Lead
Accelerating. With the China IDX anchor removed, the remaining Diagnostics business is surging. Pro forma organic revenue grew 11% in Q2, an acceleration from 9% in Q1. This segment has flipped from being a liability to the primary growth engine of the company, driven by strength in Reproductive Health and ex-China immunodiagnostics.
Life Sciences Breaks Trend
Reversing. Life Sciences pro forma organic revenue dropped 3% YoY. This is a sharp reversal from the +3% growth seen in Q1 and directly contradicts the positive narrative management has been building around their high-growth software and reagents businesses. It indicates that underlying pharma/biotech capital equipment spending remains highly constrained.
Tariff Refund Inflates Earnings
While the $1.41 adjusted EPS looks stellar on paper, it was heavily subsidized by a $16M tariff-related refund, which contributed $0.11 to the bottom line. Excluding this one-time benefit, adjusted EPS would have been $1.30. Management is smartly reinvesting this cash, but investors should strip it out when modeling structural run-rate profitability.
Macro: Pharma/Biotech Demand Remains Fragile
Despite management's previous cautious optimism about 'green shoots' in the biopharma space, the Q2 Life Sciences decline suggests the macro environment has not fully turned. The anticipated second-half recovery relies heavily on pharma customers unfreezing their budgets, which carries significant execution risk.
AI and Software Innovation
Despite broader Life Sciences weakness, Revvity's long-term bet on AI remains a core driver. Offerings like Signals Synthetica (AI models-as-a-service) and BioDesign aim to position the company as the backbone of next-gen drug discovery. As AI accelerates digital R&D, it creates a downstream demand bottleneck for Revvity's physical 'wet lab' validation tools.
Other KPIs
Accelerating. Up from 26.5% in the same period a year ago. The divestiture of the low-margin China IDX business, combined with ongoing internal cost-cutting and headcount rationalization initiatives, is creating massive operating leverage.
Accelerating. Up from $268.4 million in the first half of 2025. Strong cash generation gives the company ample ammunition to fund its aggressive share repurchase program and pay down debt.
Guidance
Accelerating. Management raised the range from their previous $2.81-$2.84B forecast. This implies confidence in a back-half acceleration, particularly in the Diagnostics segment.
Accelerating. Raised from the previous 3-4% range. Achieving the 4.5% midpoint will require the Life Sciences segment to snap back from its Q2 contraction and for Diagnostics to maintain its current double-digit momentum.
Accelerating. Raised from the prior $5.20-$5.30 range. The $0.10 bump at the midpoint almost exactly mirrors the $0.11 one-time tariff refund received in Q2, suggesting core operational earnings expectations remain relatively unchanged.
Key Questions
Life Sciences Contraction
Life Sciences pro forma organic growth dropped 3% this quarter after growing 3% in Q1. Was this driven entirely by capital equipment deferrals, or are you seeing weakness in reagents and the high-growth software portfolio as well?
Tariff Refund Reinvestment
You noted that the $16M tariff refund is being utilized for 'increased investments.' Can you specify where these dollars are being deployed and if they are one-time expenses or additions to structural OPEX?
Bridge to H2 Guidance
Achieving the raised 4-5% full-year organic growth target implies a steep acceleration in the second half. How much of this relies on a budget flush in pharma/biotech versus momentum in Diagnostics?